Experience with Biosimilar Infliximab (Remsima®) in Norway

Publisher： Karger

E-ISSN： 1421-9875|35|1-2|83-90

ISSN： 0257-2753

Source： Digestive Diseases, Vol.35, Iss.1-2, 2017-02, pp. : 83-90

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre

By  

Digestive Diseases, Vol. 35, Iss. 1-2, 2017-02 ,pp. : 91-100

Karger

Access to resources Recommend Favorite

Real-Life Efficacy, Immunogenicity and Safety of Biosimilar Infliximab

By  

Digestive Diseases, Vol. 35, Iss. 1-2, 2017-02 ,pp. : 101-106

Karger

Access to resources Recommend Favorite

Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease

By Riis Åse   Martinsen Tom C.   Waldum Helge L.   Fossmark Reidar  

Scandinavian Journal of Gastroenterology, Vol. 47, Iss. 6, 2012-06 ,pp. : 649-657

Informa Healthcare

Access to resources Recommend Favorite

Norway

By  

SourceOECD Taxation, Vol. 2011, Iss. 59, 2012-01 ,pp. : 238-252

OECD Publishing

Access to resources Recommend Favorite

Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: A Danish single center experience

By Teisner Ane Søgaard   Ainsworth Mark A   Brynskov Jørn  

Scandinavian Journal of Gastroenterology, Vol. 45, Iss. 12, 2010-12 ,pp. : 1457-1463

Informa Healthcare

Access to resources Recommend Favorite